The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Cyclin-dependent kinases regulate the antiproliferative function of Smads
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“Because cancer cells often contain high levels of CDK activit”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,385
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Seoane, J., Le, H.-V., Shen, L., Anderson, S. A., & Massagué, J. (2004) · Cell · doi:10.1016/s0092-8674(04)00298-3 · Cited by 1,028
A mechanism of repression of TGFbeta / Smad signaling by oncogenic Ras
Kretzschmar, M., Doody, J., Timokhina, I., & Massague, J. (1999) · Genes & Development · doi:10.1101/gad.13.7.804 · Cited by 1,004
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response
Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. J., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C., et al. (1999) · Nature Cell Biology · doi:10.1038/12971 · Cited by 911
Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Cited by
Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128
Massagué, J., Seoane, J., & Wotton, D. (2005) · Genes & Development · doi:10.1101/gad.1350705 · Cited by 2,452
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“CCND1: IGH translocation t(11;14)(q13;q32) Multiple myeloma 16% 185”
BackgroundTGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., & Dennis, J. W. (2007) · Cell · doi:10.1016/j.cell.2007.01.049 · Cited by 914
“Our results suggest that hexosamine/N-glycan branching may differentially regulate EGFR/PI3K/ERK and TGF-b/ SMAD signaling, which are antagonistic for G1/S transition (Matsuura et al., 2004; Siegel and Massague, 2003).”
BackgroundTGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
TGF-β Signaling from Receptors to Smads
Hata, A., & Chen, Y.-G. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022061 · Cited by 888
Contextual determinants of TGFβ action in development, immunity and cancer
David, C. J., & Massagué, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0007-0 · Cited by 851
Massagué, J., & Gomis, R. R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.033 · Cited by 721
Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719
“The Smad linker is also phosphorylated by G1 cyclin-dependent kinases during the cell cycle (Matsuura et al., 2004) and by GSK3b complementing MAPK action (Fuentealba et al.”
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
TGF-β Family Signaling in the Control of Cell Proliferation and Survival
Zhang, Y., Alexander, P. B., & Wang, X.-F. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022145 · Cited by 626
The Cell-Cycle State of Stem Cells Determines Cell Fate Propensity
Pauklin, S., & Vallier, L. (2013) · Cell · doi:10.1016/j.cell.2013.08.031 · Cited by 623
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Self-citationNon-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling
Lin, X., Duan, X., Liang, Y.-Y., Su, Y., Wrighton, K. H., Long, J., Hu, M., Davis, C. M., Wang, J., Brunicardi, F. C., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.044 · Cited by 485
Self-citationCyclins and cdks in development and cancer: a perspective
Deshpande, A., Sicinski, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 464
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
Metabolism, Cell Surface Organization, and Disease
Dennis, J. W., Nabi, I. R., & Demetriou, M. (2009) · Cell · doi:10.1016/j.cell.2009.12.008 · Cited by 450
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396
“However, recent studies have identified additional cyclin D–CDK4/6 substrates that likely contribute to the proliferative drive imposed by cyclin D–CDK4/6 activation (24, 25).”
BackgroundN-Glycans in cancer progression
Lau, K. S., & Dennis, J. W. (2008) · Glycobiology · doi:10.1093/glycob/cwn071 · Cited by 390
“Canonical TβR/SMAD2/3 signaling slows cellcycle progression by suppressing c-myc expression (Matsuura et al. 2004; Seoane et al. 2004) and recruiting protein phosphatase 2A (PP2A) which inhibits TORC1/S6K and protein synthesis (Petritsch et al. 2000) (Figure 2).”
BackgroundInfluentialUbiquitin Ligase Nedd4L Targets Activated Smad2/3 to Limit TGF-β Signaling
Gao, S., Alarcón, C., Sapkota, G., Rahman, S., Chen, P.-Y., Goerner, N., Macias, M. J., Erdjument-Bromage, H., Tempst, P., & Massagué, J. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.043 · Cited by 389
How the Smads regulate transcription
Ross, S., & Hill, C. S. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.09.006 · Cited by 383
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Phospho-control of TGF-β superfamily signaling
Wrighton, K. H., Lin, X., & Feng, X.-H. (2009) · Cell Research · doi:10.1038/cr.2008.327 · Cited by 363
A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF‐β signaling
Brown, K. A., Pietenpol, J. A., & Moses, H. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21255 · Cited by 358
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Role of Smads in TGFβ signaling
Heldin, C.-H., & Moustakas, A. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1190-x · Cited by 335
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
SMAD2,SMAD3 and SMAD4 Mutations in Colorectal Cancer
Fleming, N. I., Jorissen, R. N., Mouradov, D., Christie, M., Sakthianandeswaren, A., Palmieri, M., Day, F., Li, S., Tsui, C., Lipton, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2706 · Cited by 324
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
Topacio, B. R., Zatulovskiy, E., Cristea, S., Xie, S., Tambo, C. S., Rubin, S. M., Sage, J., Kõivomägi, M., & Skotheim, J. M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.020 · Cited by 305
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“Cyclin D1/CDK4/6 complexes phosphorylate SMAD3 and downregulate the transcription of genes involved in growth inhibition from TGF-β family [68].”
BackgroundInfluentialSignaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 261
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Tumor suppressor p16 INK4A is necessary for survival of cervical carcinoma cell lines
McLaughlin-Drubin, M. E., Park, D., & Munger, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310432110 · Cited by 163
Brett, J. O., Arjona, M., Ikeda, M., Quarta, M., de Morrée, A., Egner, I. M., Perandini, L. A., Ishak, H. D., Goshayeshi, A., Benjamin, D. I., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0190-0 · Cited by 162
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134
Feedback regulation of TGF-β signaling
Yan, X., Xiong, X., & Chen, Y.-G. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx129 · Cited by 128
Smad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
Self-citationNegative Regulation of TSC1-TSC2 by Mammalian D-Type Cyclins
Zacharek, S. J., Xiong, Y., & Shumway, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2236 · Cited by 72
“effector of proliferative control (18).”
Camarda, G., Siepi, F., Pajalunga, D., Bernardini, C., Rossi, R., Montecucco, A., Meccia, E., & Crescenzi, M. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408164 · Cited by 69
Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
Matters of context guide future research in TGFβ superfamily signaling
Akhurst, R. J., & Padgett, R. W. (2015) · Science Signaling · doi:10.1126/scisignal.aad0416 · Cited by 52
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Regulation of Renal Fibrosis by Smad3 Thr388 Phosphorylation
Qu, X., Li, X., Zheng, Y., Ren, Y., Puelles, V. G., Caruana, G., Nikolic-Paterson, D. J., & Li, J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.003 · Cited by 33
Metadata
- Authors
- Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., & Liu, F.
- Venue
- Nature
- Published
- 2004-07
- Volume
- 430
- Issue
- 6996
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2021484300
- Cited by
- 503
- References
- 30
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.